Table 3.

Application of Electronic Record–Based Algorithm to the Independent Sample of Patients With Breast Cancer From the Target Population^*: Overall and Age-Stratified Prevalence of Grades 3 and 4 Chemotherapy-Related Toxicities During Active Treatment^†

	Overall Sample		Age at Diagnosis (years)
			< 65		≥ 65
	No.	%	No.	%	No.	%
Totals	1,575	100	1,276	100	299	100
Hematologic toxicity	910	58	746	58	164	55
No
Yes	665	42	530	42	135	45
GI (diarrhea and dehydration)	1,375	87	1,123	88	252	84
No
Yes	200	13	153	12	47	16
Infectious and febrile	1,319	84	1,066	84	253	85
No
Yes	256	16	210	16	46	15
Cardiac	1,474	94	1,212	95	262	88
No
Yes	101	6	64	5	37	12
Neuropathy	1,196	76	964	76	232	78
No
Yes	379	24	312	24	67	22
Mucositis	1,515	96	1,224	96	291	97
No
Yes	60	4	52	4	8	3
Nephrotoxicity	1,561	99	1,269	99	292	98
No
Yes	14	1	7	1	7	2
Subgroup of hematologic/infectious/GI	785	50	641	50	144	48
No
Yes	790	50	635	50	155	52
Any toxicity	587	37	483	38	104	35
No
Yes	988	63	793	62	195	65

^*Study population from Kwan et al.²⁴

^†Active treatment is defined as the period from start of chemotherapy plus 12 months (or 24 months for those receiving Herceptin).